336 results about "Spinal cord lesion" patented technology

A method for restoring functional ambulation in subjects with incomplete spinal cord injuries which includes partial weight bearing therapy followed by epidural spinal cord stimulation (ESCS) to facilitate partial weight bearing therapy and over-ground walking. Electrical epidural stimulation (EES) is generated by an implanted device during partial weight bearing therapy on a treadmill. The subject is then transitioned to full weight bearing gait training on a treadmill with EES to over-ground gait training with EES and a walker, and finally to full weight bearing independent stepping over-ground with EES with or without an assistive device.

The cerebrospinal fluid and intracranial pressure are two major reasons why central nervous system is so vulnerable to injuries. A composition and method for treating injured central nervous tissue, or preventing injury to central nervous system tissue is provided. The composition is comprised of a combination of colloidal osmotic agents and crystal osmotic agents. The method comprise of: a). Withdrawing cerebrospinal fluid from the subarachnoid spaces around the tissue to be treated or protected and b). Injecting the composition which is dissolved by patient's own cerebrospinal fluid into subarachnoid spaces. The treatment can be augmented with agents that suppress production of cerebrospinal fluid, or with other known neuroprotective agents.

Methods of enabling locomotor control, postural control, voluntary control of body movements (e.g., in non-weight bearing conditions), and / or autonomic functions in a human subject having spinal cord injury, brain injury, or neurological neuromotor disease. In certain embodiments, the methods involve stimulating the spinal cord of the subject using an epidurally placed electrode array, subjecting the subject to physical training thereby generating proprioceptive and / or supraspinal signals, and optionally administering pharmacological agents to the subject. The combination of stimulation, physical training, and optional pharmacological agents modulate in real time electrophysiological properties of spinal circuits in the subject so they are activated by supraspinal information and / or proprioceptive information derived from the region of the subject where locomotor activity is to be facilitated.

The invention provides a preparation method and the application thereof for a cell-biological bracket compound based on biological print technology. The cell-biological compound is formed by fibrous protein which is drawn out from the autoblood of a patient and processed by an ink-jet print technology. The surface and the interior of the cell-biological compound encompass one or more trophic factors and bone mesenchymal stem cells derived from self. According to the invention, the biological print technology is adopted, the appearance shape, cells and encompassing state model of the trophic factors can be designed according to requirements and practical situation, the cell-biological bracket compound is obtained through printing accurately, the fibrous protein and the bone mesenchymal stem cells are derived from self, so that the problem of immunological rejection is avoided, the trophic factors are cultivated in the bracket and are released slowly with the degradation of the bracket material, the cell-biological compound is applied to the spinal cord injured part to promote nerve regeneration and functional reconstruction on the injured part.

The present invention relates to a neuronal differentiation method of adult stem cells using small molecules, more particularly to a method for inducing differentiation of adult stem cells into nerve cells using small molecules, which enables effective differentiation into nerve cells and, thus, is useful in treating intractable CNS disorders such as Parkinson's disease, dementia, Alzheimer's disease and spinal cord injury.

This application discloses alginate microencapsulation-mediated differentiation of embryonic stem cells and use of the stem cell differentiation method for the development of effective treatment of various diseases and disorders. The microencapsulation of embryonic stem (ES) cells results in decreased cell aggregation and enhanced neural lineage differentiation through incorporating the soluble inducer retinoic acid (RA) into the permeable microcapsule system. This application also discloses a micro-encapsulation system for immobilizing mesenchymal stromal cells (MSCs) while sustaining the molecular communication. Thus, the invention provides the use of encapsulated mesenchymal stromal cells in the cellular transplantation therapies. Moreover, the invention provides methods for delivery of encapsulated MSCs into the central nervous system and therapies derived therefrom, such as, the treatment of spinal cord injury (SCI) and other inflammatory conditions.

Antibodies, and particularly human antibodies, are disclosed that demonstrate activity in the treatment of demyelinating diseases as well as other diseases of the central nervous system that are of viral, bacterial or idiopathic origin, including neural dysfunction caused by spinal cord injury. Neuromodulatory agents are set forth that include and comprise a material selected from the group consisting of an antibody capable of binding structures or cells in the central nervous system, a peptide analog, a hapten, active fragments thereof, agonists thereof, mimics thereof, monomers thereof and combinations thereof. The neuromodulatory agent has one or more of the following characteristics: it is capable of inducing remyelination; binding to neural tissue; promoting Ca−− signaling with oligodendrocytes; and promoting cellular proliferation of glial cells. Amino acid and DNA sequences of exemplary antibodies are disclosed. Methods are described for treating demyelinating diseases, and diseases of the central nervous system of humans and domestic animals, using polyclonal IgM antibodies and human monoclonal antibodies sHIgm22(LYM 22), sHIgm46(LYM46) ebvHIgM MSI19D10, CB2bG8, AKJR4, CB2iE12, CB2iE7, MSI19E5 and MSI10E10, active fragments thereof and the like. The invention also extends to the use of human antibodies, fragments, peptide derivatives and like materials, and their use in diagnostic and therapeutic applications, including screening assays for the discovery of additional antibodies that bind to cells of the nervous system, particularly oligodendrocytes.

Disclosed is a wheelchair power apparatus for electronic driving conversion. It is an object of the present invention to provide a wheelchair power apparatus for electronic driving conversion, which can provide severely disabled people, for instance, patients with spinal cord injury, the weak or the old, who use wheelchairs, with convenience in movement, and convert a manual four-wheel wheelchair into an electronic three-wheel wheelchair just by detachably mounting the electronic module having electronic wheels to the existing manual four-wheel wheelchair.

The present application relates to devices and systems for rehabilitation of the locomotor system, for example limbs. In particular, the present application discloses an apparatus, more in particulara robotic platform capable of optimizing gravity-dependent trunk movements, enabling overground locomotion in non-ambulatory individuals with spinal cord injury and stroke, while promoting durable motor improvement when delivered during gait rehabilitation facilitated by electrical spinal cord stimulation.

The invention discloses a composite mesenchymal stem cell functional collagen scaffold and applications thereof. According to the present invention, isolated animal fascia is soaked sequentially withacetone, a sodium deoxycholate solution, a Triton X-100 solution, a pepsin aqueous solution and a papain solution, and free-drying is performed to obtain the composite mesenchymal stem cell functionalcollagen scaffold; the composite mesenchymal stem cell functional collagen scaffold is used for acute spinal cord injury and old spinal cord injury, and the comprehensive evaluation results from various aspects show that the composite mesenchymal stem cell functional collagen scaffold can substantially promote the movement function recovery, nerve regeneration, axon myelination and synapse formation of acute and old spinal cord injury dogs; and the functional biomaterial can provide great significance in the repair of spinal cord injury, and can provide theoretical support for the applicationof functional biomaterials in the future.

The invention provides a method for preparing motoneuron-like cells derived from adipose stem cells. The method comprises the following steps: treating 3-6 generations of high-purity adipose stem cells by using a motoneuron-like cell inducer to obtain motoneuron-like cells; and treating the adipose stem cells by using the motoneuron-like cell inducer, and then treating continuously by using neurotrophic factors, thereby obtaining more mature motoneuron-like cells. By adopting the method provided by the invention, the more mature motoneuron-like cells derived from the adipose stem cells can be obtained in an extremely short time, and the obtained motoneuron-like cells can be used for preventing or treating motoneuron injuries and spinal cord injuries; and the pre-induced motoneuron-like cells obtained by the method provided by the invention can be better used for preventing and treating the motoneuron injuries and spinal cord injuries.

The present invention relates to methods of inducing neurite outgrowth in the central nervous system by antagonizing neural growth inhibitory factors. More particularly, the present invention is directed to use of antibodies to the central nervous system (CNS) myelin associated proteins; such antibodies can be used in the diagnosis and therapies of nerve damage resulting from trauma, infarction, and degenerative disorders of the CNS. In a specific embodiment of the invention, the monoclonal antibody IN-1 may be used to promote neurite outgrowth of nerve fibers over long distances in spinal cord lesions.

A method of diagnosing central nervous system injuries such as acquired brain injury (ABI) and / or acquired spinal cord injury (ASI), including mild TBI (concussion or blast wave), mild ASI (contusion,stretch or partial cord transection), non-TBI brain injury and / or non-TSI spinal cord injury in a subject (animal or human). The method includes (a) obtaining a biological test sample from the subject, identifying metabolites in the subject's sample using metabolomics thereby obtaining a subject's metabolite matrix and generating a subject's profile using the patient's metabolite matrix; and (b)using multivariate statistical analysis and machine learning to compare the subject's profile with predetermined set of profiles of CNS injuries and a predetermined set of profiles of controls to determine if the subject has a CNS injury.

This application discloses a light-responsive hydrogel-based platform that can modulate multiple microenvironmental signals to direct the differentiation of human induced pluripotent stem cell-derived neural progenitor cells (hiPSC-NPCs) into neuronal cells. The invention provides novel methods for directing differentiation of neural stem cells into neurons useful for treatment of degenerative diseases or disorders, including but not limited to Alzheimer's, Parkinson's, or spinal cord injury (SCI).